Tuesday, February 26, 2019

Amgen Prevails In Cholesterol Drug Battle With Sanofi

Thousand Oaks-based Amgen has scored a win in court, after a jury upheld two patents held by the company for its drug Repatha, which is used to treat ultra-high LDL cholesterol. Amgen had been sued by Sanofi and Regeneron Pharmaceuticals over patent infringement. Sanofi and Regeneron make their own, cholesterol-lowering drug, called Praluent. Amgen, Sanofi, and Regeneron have been battling each other over their respective cholesterol drugs since 2014. Sanofi and Regeneron said they plan to appeal the part of the verdict they lost. Both Repatha and Praluent are used to treat people with ultra high LDL cholestorol; the two are PCSK9 inhibitors.